29284-76-2

Usage

Uses

Used in Pharmaceutical Industry:
2,3-DICHLORO-6-NITRO-1,4-NAPHTHOQUINONE is used as an intermediate in the synthesis of pharmaceuticals for its ability to be further modified and incorporated into drug molecules. Its electron-withdrawing and electron-donating properties make it a valuable building block in the development of new therapeutic agents.
Used in Dye Industry:
In the dye industry, 2,3-DICHLORO-6-NITRO-1,4-NAPHTHOQUINONE is used as an intermediate in the production of various dyes. Its unique chemical structure allows for the creation of dyes with specific color properties and stability.
Used in Organic Synthesis:
2,3-DICHLORO-6-NITRO-1,4-NAPHTHOQUINONE is used as a reagent in organic synthesis due to its electron-withdrawing and electron-donating properties. These properties enable it to participate in a wide range of chemical reactions, facilitating the formation of new compounds and contributing to the advancement of organic chemistry.
Used in Biological Research:
2,3-DICHLORO-6-NITRO-1,4-NAPHTHOQUINONE has been studied for its potential biological activities, including cytotoxic and anti-tumor properties. Researchers are exploring its potential as a therapeutic agent in the treatment of various diseases, particularly cancer.

InChI:InChI=1/C10H3Cl2NO4/c11-7-8(12)10(15)6-3-4(13(16)17)1-2-5(6)9(7)14/h1-3H

Upstream product

• 117-80-6 2,3-Dichloro-1,4-naphthoquinone 
• 58200-82-1 6-nitro-1,4-naphthoquinone 

Downstream Products

• 62345-17-9 2,3,6-Trimethoxy-[1,4]naphthochinon 
• 634612-24-1 7-nitro-2-(N-3,4-difluoroanilino)-3-pyrrolidino-1,4-naphthoquinone 
• 1204290-52-7 4-(3-chloro-7-nitro-1,4-dioxo-1,4-dihydronaphthalen-2-ylamino)-N-(pyridin-2-yl)benzenesulfonamide 
• 1204290-51-6 4-(3-chloro-6-nitro-1,4-dioxo-1,4-dihydronaphthalen-2-ylamino)-N-(pyridin-2-yl)benzenesulfonamide 
• 1204290-54-9 4-(7-amino-3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-ylamino)-N-(pyridin-2-yl)benzenesulfonamide 
• 1204290-53-8 4-(6-amino-3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-ylamino)-N-(pyridin-2-yl)benzenesulfonamide 
• 1610042-76-6 N-(3-(3,5-dimethylphenylamino)-6-nitro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide 
• 1610042-77-7 N-(3-(3,5-dimethylphenylamino)-7-nitro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide 
• 1610042-79-9 N-(6-amino-3-(3,5-dimethylphenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide 
• 1610042-80-2 N-(7-amino-3-(3,5-dimethylphenylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzenesulfonamide 
• 1610042-74-4 C₁₆H₉ClN₂O₆S 
• 1610042-75-5 C₁₆H₉ClN₂O₆S 

Relevant academic research and scientific papers

TARGETED PEPTIDE CONJUGATES

The present invention relates to the preparation and use of therapeutic compounds for the treatment of diseases at specific subcellular target areas such as specific cellular organelles. In particular, the therapeutic compounds of the invention are specific for modifying enzyme activity within targeted organelles or structures of cells and tissues. Subcellular organelles and structures that may be specifically targeted by compounds of the present invention include lysosomes, autophagasomes, the endoplasmic reticulum, the Golgi complex, peroxisomes, the nucleus, membranes and the mitochondria.

Activity-Based Probes for Isoenzyme- and Site-Specific Functional Characterization of Glutathione S-Transferases

Glutathione S-transferases (GSTs) comprise a diverse family of phase II drug metabolizing enzymes whose shared function is the conjugation of reduced glutathione (GSH) to endo- and xenobiotics. Although the conglomerate activity of these enzymes can be measured, the isoform-specific contribution to the metabolism of xenobiotics in complex biological samples has not been possible. We have developed two activity-based probes (ABPs) that characterize active GSTs in mammalian tissues. The GST active site is composed of a GSH binding "G site" and a substrate binding "H site". Therefore, we developed (1) a GSH-based photoaffinity probe (GSTABP-G) to target the "G site", and (2) an ABP designed to mimic a substrate molecule and have "H site" activity (GSTABP-H). The GSTABP-G features a photoreactive moiety for UV-induced covalent binding to GSTs and GSH-binding enzymes. The GSTABP-H is a derivative of a known mechanism-based GST inhibitor that binds within the active site and inhibits GST activity. Validation of probe targets and "G" and "H" site specificity was carried out using a series of competition experiments in the liver. Herein, we present robust tools for the characterization of enzyme- and active site-specific GST activity in mammalian model systems.

Identification of compounds for the treatment or prevention of proliferative diseases

The invention features compounds for the treatment of cancer and other proliferative diseases. These compounds were identified in screening assays that contact candidate compounds with a cell containing a nucleic acid that includes a HER2 regulatory element and a reporter sequence. The invention further features compounds structurally related to those identified by the screening assays. Finally, the invention features methods of treating or preventing a proliferative disease using the compounds of the invention.

Topical Nonsteroidal Antipsoriatic Agents. 1. 1,2,3,4-Tetraoxygenated Naphthalene Derivatives

On the basis of previous observations that both 2,3-dihydro-2,2,3,3-tetrahydroxy-1,4-naphthoquinone (oxoline, 1) and 6-chloroisonaphthazarin (2) had demonstrated antipsoriatic activity in vivo, a series of structural derivatives of 2 were prepared and examined in the Scholtz-Dumas topical psoriasis bioassay.Of these six (5, 6, 9a, 10, 11a, 11b), the most effective compound was found to be 6-chloro-1,4-diacetoxy-2,3-dimethoxynaphthalene (RS-43179,lonapalene, 11a).An extensive series of 1,2,3,4-tetraoxygenated naphthalenes (16-74) incorporating variations of the ester, eth er and aryl substituents were prepared as analogues of 11a to examine the structural requirements for activity and were screened in vivo as inhibitors of arachidonic acid induced mouse ear edema, a topical bioassay capable of detecting 5-lipoxygenase inhibitors.Net lipophilicity, hydrolytic stability, and ring substitution play significant roles in determining the observed in vivo activity.Lonapalene (11a) is currently in clinical development as a topical applied nonsteroidal antipsoriatic agent.